Hemab Therapeutics Inc. Common Stock
COAG | NASDAQ
$41.38
+$0.96 (+2.38%)
At close: Oct 30, 2026, 3:59 PM ET
$41.66
+$0.28 (+0.68%)
After-hours:
Oct 30, 2026, 7:48 PM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 |
|---|---|---|
Net Income | -24.15M | -22.69M |
Depreciation & Amortization | -73K | 73K |
Stock-Based Compensation | n/a | 1.32M |
Other Working Capital | -427K | 427K |
Other Non-Cash Items | 2.01M | -663K |
Deferred Income Tax | n/a | n/a |
Change in Working Capital | -427K | 375K |
Operating Cash Flow | -22.64M | -21.58M |
Capital Expenditures | 112K | -112K |
Cash Acquisitions | n/a | n/a |
Purchase of Investments | -132.47M | -15.74M |
Sales Maturities Of Investments | 25.06M | n/a |
Other Investing Acitivies | -135K | n/a |
Investing Cash Flow | -107.44M | -15.85M |
Debt Repayment | n/a | -46K |
Common Stock Repurchased | n/a | n/a |
Dividend Paid | n/a | n/a |
Other Financial Acitivies | n/a | -414K |
Financial Cash Flow | 317.58M | -460K |
Net Cash Flow | 187.51M | -38.11M |
Free Cash Flow | -22.53M | -21.7M |
Adj. Free Cash Flow | -22.53M | -23.01M |
Maintenance CapEx | -73K | -73K |
Growth CapEx | 185K | -39K |
Owner Earnings | -22.71M | -21.66M |
Add to Watchlist
Select watchlists to add or remove COAG